Treatment of hallucinosis/psychosis in Parkinson's disease by an investigational drug

Trial Profile

Treatment of hallucinosis/psychosis in Parkinson's disease by an investigational drug

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2015

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Parkinson's disease; Psychotic disorders
  • Focus Therapeutic Use
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 18 Jun 2015 Pooled analysis of two extension trials (ACP103-010, ACP103-015) for long-term efficacy: results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 16 Jun 2015 According to an Acadia Pharmaceuticals media release, data from this study were presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 01 Mar 2010 Efficacy results published in Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top